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Meningococcal serogroups and surveillance:  
a systematic review and survey
Background Meningococcal disease continues to be a global 
public health concern due to its epidemic potential, severity, 
and sequelae. The global epidemiological data on circulating 
meningococcal serogroups have never been reviewed concur-
rently with the laboratory capacity for meningococcal surveil-
lance at the national level. We, therefore, aimed to conduct a 
country-level review of meningococcal surveillance, serogroup 
distribution, and vaccine use.
Methods We conducted a systematic literature review across 
six databases to identify studies (published January 1, 2010 to 
October 16, 2017) and grey literature reporting meningococ-
cal serogroup data for the years 2010-2016. We performed in-
dependent random effects meta-analyses for serogroups A, B, 
C, W, X, Y, and other. We developed and circulated a ques-
tionnaire-based survey to surveillance focal points in countries 
(N = 95) with known regional bacterial meningitis surveillance 
programs to assess their surveillance capacity and summarized 
using descriptive methods.
Results We included 173 studies from 59 countries in the fi-
nal analysis. The distribution of meningococcal serogroups dif-
fered markedly between countries and regions. Meningococcal 
serogroups C and W accounted for substantial proportions of 
meningococcal disease in most of Africa and Latin America. Se-
rogroup B was the predominant cause of meningococcal disease 
in many locations in Europe, the Americas, and the Western 
Pacific. Serogroup Y also caused many cases of meningococcal 
disease in these regions, particularly in Nordic countries. Sur-
vey responses were received from 51 countries. All countries 
reported the ability to confirm the pathogen in-country, while 
approximately 30% either relied on reference laboratories for 
serogrouping (N = 10) or did not serogroup specimens (N = 5). 
Approximately half of countries did not utilize active laborato-
ry-based surveillance system (N = 22). Nationwide use of a me-
ningococcal vaccine varied, but most countries (N = 36) utilized 
a meningococcal vaccine at least for certain high-risk population 
groups, in private care, or during outbreaks.
Conclusions Due to the large geographical variations in circu-
lating meningococcal serogroups, each country should contin-
ue to be monitored for changes in major disease-causing sero-
groups in order to inform vaccine and control policies. Similarly, 
laboratory capacity should be appropriately scaled up to more 
accurately understand local epidemiology and disease burden, 
as well as the impact of vaccination programs.
Electronic supplementary material: 
The online version of this article contains supplementary material.
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Invasive meningococcal disease (IMD), caused by the bacteria Neisseria meningitidis, most commonly man-
ifests as meningitis or septicemia [1]. Historically, more than 80% of cases were fatal [2,3]. Despite the 
availability of effective antibiotics, IMD is still associated with a case fatality rate of approximately 10%-
15% [4,5], which can increase to 40% for meningococcemia cases during outbreaks [5,6]. Approximately 
10%-20% of survivors have severe neurological, visual, or hearing impairments, rates of which are often 
higher in low-resource settings [5,7,8]. Approximately 1.2 million cases of IMD occur each year, result-
ing in about 335 000 deaths worldwide [1]. The burden of IMD is disproportionately higher in the Afri-
can meningitis belt which has had the greatest number of meningococcal epidemics [9]. IMD incidence 
is highest among infants and children under 5, with a second peak in incidence among adolescents [9]. 
Additionally, IMD outbreaks have been reported among university students, military recruits, and Hajj 
pilgrims [10-13].
Virulent Neisseria meningitidis is predominantly encapsulated, and of the 12 identified capsular serogroups, 
A (NmA), B (NmB), C (NmC), W (NmW), X (NmX), and Y (NmY) cause the vast majority of IMD cas-
es [14]. The dynamic epidemiology of these serogroups is unpredictable and varies with time and geo-
graphical region [15]. Knowledge of the local serogroup prevalence is gained through adequate surveil-
lance activities within a country. Additionally, surveillance provides data on disease burden and outbreak 
detection. Together, this information guides vaccine and prevention policies [16].
Immunization against IMD is the best prevention method. Currently, there are vaccines available for all 
major disease-causing serogroups (A, B, C, W, and Y) except serogroup X, which has multiple versions in 
development [17,18]. Although, it should be noted that the vaccine targeting serogroup B is only broadly 
protective and does not cover all strains causing disease [19]. Meningococcal vaccines are serogroup spe-
cific, or protein-specific in the case of the vaccines targeting serogroup B [19], thus further necessitating 
the knowledge of the circulating serogroups within a country. Although surveillance capacity is needed to 
determine the direct and indirect effects of existing vaccines and any newly introduced vaccines [15,16], 
many countries either do not have laboratory-based meningococcal surveillance systems or have limited 
participation in surveillance activities [15,20-22]. The development of effective vaccine policies and de-
termination of suitable vaccines for use in a country is dependent upon the local serogroup epidemiology 
and cost-effectiveness. Although laboratory capacity, serogroup distribution, and vaccine use have been 
reviewed for select countries prior to 2010 [23-28], to our knowledge, no recent article has provided 
the comprehensive data on these three aspects globally for the post-2010 period. Since these topics are 
interrelated, we aimed to conduct a country-level review of meningococcal surveillance through the in-
vestigation of current serogroup distribution, global laboratory capacity for meningococcal surveillance, 
and vaccine use within countries.
METHODS
Search strategy and data sources
We conducted a systematic literature review to identify published studies reporting meningococcal sero-
group data according to a pre-specified protocol (PROSPERO number CRD42017080219). We identified 
articles published from January 1, 2010 to October 16, 2017 that reported country specific invasive me-
ningococcal disease serogroup data for 2010-2016 from 6 databases: MEDLINE, Embase, Web of Science 
Core Collection, Current Contents Connect, WHO Global Health Library, and Global Health Database. 
Detailed search strategy including search terms can be found in the Supplementary material. No restric-
tion was made based upon language. Where required, we used Google Translate to assist in translation 
of non-English language articles. Additionally, we sought assistance of a native speaker and/or contacted 
authors to seek clarifications. We also identified unpublished national surveillance data by searching rel-
evant ministry of health and surveillance network websites for each country.
Inclusion and exclusion criteria
Studies or surveillance reports were included if they: reported meningococcal serogroup data from typi-
cally sterile sites in humans; clearly specified the number of samples tested and the serogroups identified; 
clearly described the time period and country of specimen collection; reported the majority of data be-
tween January 1, 2010 and December 31, 2016; and had a sample size of at least 15 (or an average of 15 
per year if reporting for more than one year). Studies in all age groups were eligible for inclusion. Studies 
from outbreak periods were eligible for inclusion. Studies were excluded if they were conducted only in 
a select population (ie, patients with asplenia) or only tested for one serogroup.
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Data collection and management
Two authors (MEP and YL) independently reviewed full text articles and extracted relevant data into a 
database in Microsoft Access. Any differences in extraction were resolved through discussion. Only one 
study was chosen for each geographic area and time period. If multiple studies were identified for the 
same location and time period, the choice between studies was based upon quality, representativeness of 
geographic area, number of serogroups reported, recent study year, and sample size. We contacted au-
thors of identified publications for any relevant additional information. For several countries in the men-
ingitis belt, multiple studies were identified where the risk of duplicate data could not be reconciled. The 
two primary reasons included: multiple studies stating the data are reported from the same sources, yet 
the studies provide different data; and uncertainty about the representativeness of the studies. In these 
instances, the study that was deemed to be most representative with the largest sample size was included 
in the analysis, and the remaining are detailed in Table S1 in Online Supplementary Document. Ques-
tions concerning appropriateness for inclusion in analysis were discussed between MEP, YL, HN, and 
MHK and agreed upon prior to proceeding to analysis.
Data analysis
We conducted meta-analyses per serogroup: NmA, NmB, NmC, NmW, NmX, NmY, and Other Nm 
(which includes non-groupable, non-encapsulated, NmE, NmE/Z, NmZ, polyagglutinable, and incom-
pletely identified serogroups). All reported serogroups were included in the calculation of the denomina-
tor, while unknown or untested samples were excluded. In cases where we could be reasonably certain 
that a serogroup was tested for, but simply not reported because there were zero cases, we included an 
assumed zero for that serogroup (Table S3 in the Online Supplementary Document). If a study reported 
serogroup data by year, each year was included as a separate datapoint in the analysis. In order to calcu-
late a point estimate for each country, a random effects model using exact binomial confidence intervals 
and the Freeman-Tukey transformation were utilized. All analyses were performed in StataIC 13 (64-bit) 
with the metaprop command [29]. Results are organized by WHO Regions.
Survey design and distribution
We developed and piloted a questionnaire (Table S2 in Online Supplementary Document) with specif-
ic reference to general meningococcal surveillance and laboratory capacity for surveillance. After drafting 
the survey, we circulated it to several content experts who reviewed it for content validity and revised it 
according to their suggestions. We then contacted WHO Regional Office staff involved with the Glob-
al Invasive Bacterial Vaccine Preventable Diseases (IB-VPD) Surveillance Network (GISN) and European 
Centre for Disease Prevention and Control (ECDC) officers and sought their assistance to invite national 
Ministry of Health or Surveillance Programme officers to participate in this exercise. The questionnaire 
was sent to the regional contacts between October 25, 2016 and November 11, 2016, and reminders 
were sent as part of regular follow up if survey was not received.
Questionnaire analysis
Completed questionnaires were extracted into Microsoft Access by MEP and independently crosschecked 
by YL. If upon review of the responses clarifications were needed, questions were sent to the country-lev-
el contact for more detail. The data from the questionnaires were synthesized using descriptive methods. 
We used WHO Regional classification to compare laboratory capacity for surveillance at the regional level.
RESULTS
We identified a total of 7637 articles through literature review and an additional 181 through hand search-
ing. We reviewed 994 articles in full and identified 173 articles meeting our strict eligibility criteria and 
reporting relevant data (Figure 1). We included data from 59 countries, representing, at least partially, all 
six WHO regions. Study characteristics can be found in Table S3 in the Online Supplementary Docu-
ment. Data availability differed substantially between WHO regions (Table S3 in Online Supplementary 
Document). The regions with greatest representation included the European (EURO), African (AFRO), 
and the Americas (AMRO) with 51% (27/53), 36% (17/47), and 26% (9/35) of countries with data in-
cluded, respectively. Within AFRO, substantially more data were available for the meningitis belt (60%, 
15/25) compared to non-meningitis belt (9%, 2/22). The remaining three WHO regions had substantially 
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less representation. Data from only 15% (4/27) of the Western Pacific (WPRO), 10% (2/21) of the Eastern 
Mediterranean (EMRO), and 9% (1/11) South-East Asian (SEARO) were included in the analysis. Results 
of country-level meta-analyses (by WHO region) are presented in Table 1.
We observed substantial differences in the distribution of meningococcal serogroups by country and re-
gion (Table 1, Figure 2). Due in part to the dynamic nature of N. meningitidis serogroup distribution 
Figure 1. PRISMA flowchart of included studies.
Figure 2. Countries included in serogroup review. Serogroups shown represent an estimated ≥25% of cases 
for 2010-2016.
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during this time period (Figures S1-S4 in Online Supplementary Document), heterogeneity was elevat-
ed for many serogroup analyses (Table S4 in Online Supplementary Document).
NmW was the predominant circulating serogroup (range: 43.9%-98.2%) throughout most of AFRO, ex-
cept Algeria, Cameroon, Chad, Guinea and Nigeria. NmA was the most prevalent (range: 76.2%-97.3%) 
in Cameroon, Chad, and Guinea, while Nigeria was the only country with NmC as the most prevalent 
(100.0%). The next most prevalent serogroup varied greatly within this region. For example, NmA rep-
resented only 0.2% of circulating serogroups in Togo, while NmX represented 22.5% of those within 
Burkina Faso. Algeria and South Africa were the only countries in AFRO with substantial NmB circula-
tion (59.3% and 29.1%, respectively).
NmB was the most prevalent serogroup in the USA, Canada, Argentina, Colombia, and Uruguay (range: 
30.8%-73.0%). Elsewhere in the Americas, either NmC (Brazil, Mexico, and Venezuela; range: 52.8%-
88.2%) or NmW (Chile, 51.7%) was the most predominant. The second most prevalent circulating se-
rogroup within AMRO was NmB within most of Latin America (range: 11.8%-37.9%) and NmY within 
North America (range: 23.6%-25.6%).
Within EURO, NmB predominated in nearly all countries (range: 40.7%-91.7%). In countries where NmB 
was not the most prominent, NmY was the most prevalent serogroup in Norway and Sweden (37.3% 
and 42.4%, respectively), NmW in Turkey (47.2% of cases), and NmA in Kyrgyzstan (89.6% of cases).
India was the only country in SEARO included in the analysis, where all reported cases were identified 
as NmA. Similarly, Sudan was the only country within EMRO included in the analysis. NmA accounted 
for 90.0% of all IMD cases.
In WPRO, NmB was the primary cause of IMD in both Australia and New Zealand (72.5% and 63.3%, 
respectively) while, NmC was the prominent circulating serogroup within China (40.3%), and NmY in 
Japan (61.0%).
We circulated and received a response to participate in our questionnaire-based survey to understand 
the laboratory capacity for meningococcal surveillance from all WHO regions except AMRO. Response 
rate was high in EURO, with 67% (4/6) of GISN participating countries responding and 53% (16/30) of 
ECDC participating countries responding. Similarly, response rate was high in AFRO with 47% (22/47) 
of countries responding (18 of which are located within the extended meningitis belt). GISN participating 
countries in WPRO and SEARO also had high response rates at 83% (5/6) and 100% (3/3), respectively. 
Response rate was lowest among GISN participating countries in EMRO where only 25% (1/4) responded.
Among the participating countries, there were differences in surveillance coverage. Within AFRO, 68% of 
countries had the entire country under surveillance while none of EMRO and SEARO had countrywide 
surveillance (Table 2). Twenty percent of participants from WPRO had the entire country under sur-
veillance. This number was demonstrably higher within EURO where 89% of the respondents reported 
country level meningococcal surveillance. Most regions, except AFRO and EURO, primarily focused on 
surveillance in children younger than five years of age.
In all respondent countries, surveillance was primarily supported by funding from the government and 
‘other’ sources, which included WHO, local support, research projects, donors, and industry grants. Gov-
ernment support ranged from 60% of countries in WPRO to 100% in EMRO and SEARO.
All participating countries utilized surveillance data to primarily better understand the epidemiology of 
meningococcal disease within their country. A secondary aim of most countries (71%, 35/49) was to mea-
sure the impact of interventions and vaccines.
The majority of regions had PCR capabilities for both pathogen detection and serogrouping. Fifty percent 
of countries within AFRO and SEARO utilized PCR for pathogen detection, while countries within EURO 
and WPRO utilized PCR more frequently for pathogen detection (100% and 80%, respectively). Use of 
PCR for genogrouping was high within EURO (75%), while only 30% of countries in AFRO used PCR 
for genogrouping in-country and 20% utilized a regional reference laboratory for this purpose.
The majority of all regions were regularly performing antimicrobial resistance testing. The specific antibi-
otics tested for in each region can be found in Table S6 in Online Supplementary Document.
Overall, meningococcal vaccine use within the national immunization schedule was low. No countries with-
in SEARO or WPRO included any meningococcal vaccine in a national schedule, and only 13% of AFRO 
and 35% of EURO did so. Although nationwide use of the vaccine was low, use within high-risk groups 
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or availability within the private sector was higher for EURO, SEARO, and WPRO (80%, 100%, and 75%, 
respectively). Thirteen percent of countries within AFRO used a meningococcal vaccine in this manner. 
No use of the vaccine in any form was highest within AFRO (30%), WPRO (25%), and EURO (20%).
DISCUSSION
Our review demonstrates that there is substantial variability (between countries and WHO regions) in the 
predominantly circulating meningococcal serogroups. Our survey to determine the laboratory capacity 
for meningococcal surveillance expands upon previous knowledge and complements the ECDC labora-
tory capability monitoring system, GISN technical working group meeting reports, and Global Meningo-
coccal Initiative (GMI) roundtable meeting summaries by providing an updated status of meningococcal 
disease surveillance in comparison to other regions globally [15,16,20-22,30-32]. These results highlight 
the need for continued efforts in meningococcal surveillance and laboratory capacity to accurately assess 
the burden of serogroup-specific meningococcal disease and to identify groups at high-risk for menin-
gococcal disease.
Multiple factors within each country can affect the circulating meningococcal serogroups, including vac-
cine use and outbreaks. Our study showed that serogroup B caused the majority of IMD cases in many 
countries throughout EURO, WPRO, and AMRO, where the inclusion of either MenC or MenACWY, 
but not MenB, in the national immunization schedule predominates (data not shown) [33,34]. The ex-
perience in the UK highlights how the proportional increase of NmB occurred after introduction of the 
MenC vaccine. Prior to the introduction of MenC vaccine in the UK in 1999, NmB and NmC caused 
approximately 50% and 35% of all cases, respectively [35]. Approximately a decade after the introduc-
tion of MenC, NmB accounted for 87% of IMD cases in England and Wales, and NmC only 2% [36]. 
Although overall incidence declined during this period, the high incidence of NmB disease and severe 
sequelae among infants, led to the introduction of a national MenB vaccine in the UK in 2015 [37]. Sim-
ilarly, NmA has substantially decreased in AFRO after the introduction of a MenA conjugate vaccine af-
ter years of widespread epidemics in the meningitis belt [38,39]. In addition to the influence of nation-
al vaccination programs to control previously endemic circulating serogroups such as described above, 
recent outbreaks have led to the introduction of new national vaccination programs. Examples include 
increased NmW cases in the UK [40], Chile, and Argentina [15], and the NmC epidemic in Niger (intro-
duction in process, data not shown).
Due to the epidemic potential of meningococcal disease, it is important to establish a systematic surveil-
lance system in each country, or at least in countries prone to large-scale outbreaks, such as in the African 
meningitis belt. This should be done in order to quickly identify the outbreak; implement effective control 
measures, such as accessing vaccine stockpiles; and developing preventive policies against the occurrence 
of outbreaks and control of endemics. For instance, in Chile, increased incidence of NmW and high case 
fatality rates led to the establishment of mandatory notification surveillance system and targeted vaccina-
tion among children [20]. Similarly, Burkina Faso is another striking example of how strategic laboratory 
capacity development can support the introduction of a vaccine into the national immunization program. 
From 2007 to 2011, the proportion of isolates received by a reference laboratory for confirmation and 
serogrouping increased from 11% to approximately 85% [24]. This rapid expansion in capacity for ac-
tive, cased-based surveillance provided the evidence base to monitor the impact of the MenA vaccine on 
IMD burden. This was accomplished through assessment, training, mentorship, and technology transfer 
[38], displaying the benefit of strategic partnerships for capacity development. However, long-term sus-
tainability of the increased capacity is vital in order to see future improvements in surveillance practices. 
In addition to monitoring vaccine effects, routine surveillance data provide information on the temporal 
trends of IMD, a dynamic disease. The ability to monitor for outbreaks and determine circulating sero-
groups and incidence are all dependent on the quality and representativeness surveillance data and lab-
oratory capacity. Our survey results highlight this point as many of the countries that were conducting 
surveillance in limited populations or sites did not have publically available serogroup data.
Our survey identified the continued need to expand laboratory infrastructure and capacity for identifying 
meningococcus, serogrouping, and antibiotic susceptibility testing. This is especially necessary to differ-
entiate meningococcal outbreaks from those caused by other organisms, such as Streptococcus pneumo-
niae, as recently seen in Ghana [41]. Ideally the countries with surveillance only in part of the country or 
passive surveillance, which comprise approximately half of countries participating in this survey, would 
expand to active, case-based surveillance systems. This would provide a more accurate understanding 
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of serogroup specific disease burden in these countries. Although data from passive surveillance covers 
many provinces, or sometimes the entire country, these can often be delayed and incomplete. Sentinel 
surveillance provides some of the necessary details to understand vaccine effects, but does not provide the 
breadth of coverage as other methods, nor does it allow for understanding of disease incidence. Addition-
ally, the representativeness of sentinel site data are also directly dependent on the size of the catchment 
area and the proportion of patients with meningococcal disease that reach the sentinel site for treatment. 
In contrast, national, active case-based surveillance allows for more complete understanding of how in-
terventions, such as vaccine implementation, have affected overall meningococcal incidence and epide-
miology. However, we realize this method of surveillance is the most time- and resource-consuming and, 
therefore, is not currently feasible for many countries, especially those with limited laboratory capacity. 
In this case, improving the existing sentinel or passive surveillance systems to promote data completeness 
and timely reporting should be a priority [42].
Strengths of this study include the comprehensive systematic literature review and grey literature search 
to identify meningococcal serogroup data. Many countries are conducting meningococcal surveillance, 
but only publish reports on their respective websites. We initially planned to search the Chinese literature 
databases, but during the hand searching process, national data were identified for China. Therefore, the 
Chinese databases were not included in this search. An additional strength includes collecting primary 
meningococcal surveillance data from country-level contacts. Although previous reviews have reported 
discussions in expert panels and meetings regarding laboratory capacity for meningococcal surveillance 
[15,16,20-22,32], to our knowledge, this is the first study to provide extensive details about IMD sur-
veillance in several parts of the world.
However, this review is not without its limitations. The quality of the serogroup estimates within this study 
is highly dependent upon the quality of data available from each country. The sample size that each se-
rogroup distribution estimate is based upon impacts its reliability. Even for countries participating in es-
tablished surveillance networks, such as SIREVA-II within Latin America, the proportion of isolates from 
reported cases sent to reference laboratories for characterization is not uniform across all countries, and 
neither are case definitions or surveillance practices [15,20]. Our decision to only include studies that 
report serogroup data for at least 15 specimens per year meant exclusion of data from countries that did 
not meet this eligibility criteria (Table S5 in Online Supplementary Document). In addition, dynamic 
changes in circulating serogroups during the study period due to large epidemics, such as recently report-
ed NmC in Niger and Nigeria [43]; recent natural shifts in predominant serogroups, such as increased 
NmW in Australia, England, and the Netherlands [44,45]; or vaccine-induced shifts, as in the African 
meningitis belt [38,39]; would affect the reported serogroup estimates from these countries. Similarly 
for Benin and India, where only outbreak reports were included in analysis, the serogroup prevalence of 
the outbreak causing serogroup could be overestimated. It is a known concern that meningococcal data 
from India heavily relies on data primarily collected during outbreaks, and IMD disease burden could be 
underestimated in the country [21]. For these reasons, the reported serogroup meta-estimates should be 
interpreted with caution. We would encourage that the serogroup data presented herein be interpreted 
together with the reported laboratory capacity data and meningococcal disease incidence data [26]. This 
can aid policy makers in determining the need for advanced meningococcal surveillance and introduc-
tion/scaling up of meningococcal vaccination in their country.
When utilizing surveys for data collection, missing countries and/or missing data may bias the results of 
the study by not allowing for a complete assessment of surveillance capacity. Additionally, reporting bias 
could influence the results. We attempted to overcome this limitation by allowing the country-level con-
tacts an opportunity to review interpretation of their data prior to publication. While all countries with 
WHO and ECDC supported meningococcal surveillance programs were contacted, there are countries 
outside of these networks that were not asked to participate in this review. Limitations notwithstanding, 
these results should provide valuable details for countries where this information was previously not pub-
lically known. Since this study primarily focused on basic characterization of laboratory capacity, further 
research is required to determine the advanced capabilities for meningococcal surveillance globally, such 
as multilocus sequence typing (MLST) or whole genome sequencing (WGS).
CONCLUSIONS
Our study highlights that the serogroup distribution continues to vary by country and WHO region and 
reports the laboratory capacity for surveillance in multiple regions. Countries should continue monitor-
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ing the circulating meningococcal serogroups and strengthen laboratory capacity as is appropriate in their 
context. These data can inform disease burden estimates and future vaccination policies or evaluations. 
Additionally, as molecular testing becomes increasingly more affordable, meningococcal surveillance will 
continue to play an important role in understanding the emergence and global spread of hypervirulent 
clonal complexes.
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